Congress Took 42 Days on Average to Disclose Stock Trades in 2023. The Law Says 30 or Face Fines.

Republicans conducted 200 trades compared to 150 by Democrats during this period—a 78% share of all congressional trading activity. But Republicans don't hold 78% of congressional seats. They hold roughly half.

This means Republican members of Congress are trading individual stocks at significantly higher rates than their Democratic counterparts. For every Democrat making a trade, roughly 1.3 Republicans are doing the same. This isn't about party size—it's about trading culture.

While Americans debated prescription drug prices, Medicare expansion, and pandemic recovery measures, members of Congress were busy trading healthcare stocks. 30 trades—the single largest sector by volume—involved healthcare companies like Pfizer, which alone accounted for 10 trades, making it the most-traded stock in the entire dataset.

This isn't just about volume. It's about timing and access. Members of Congress sit on committees that regulate drug prices, approve FDA budgets, and shape pandemic response policy. They receive classified briefings about public health threats. They vote on legislation that can send a pharmaceutical stock soaring or plummeting.

Here's the pattern that should alarm every American: trades exceeding $1 million—considered outliers in the dataset—took longer to disclose than smaller trades. While the median disclosure time was 31 days, transactions in the millions routinely pushed past 45 days or more, with some hitting the legal maximum of 90 days.

This isn't random. It's strategic. The STOCK Act requires disclosure within 30 or 45 days depending on the type of transaction, with minimal fines for violations. But when you're trading $2.5 million to $5 million in a single transaction—as several politicians did—a $200-per-day fine is a rounding error.

By the time you learn about a senator's multi-million dollar pharmaceutical purchase, the stock has already moved, the profit is already locked in, and your chance to follow along is already gone.

The Senate conducted 220 trades compared to 230 in the House. That sounds roughly equal—until you remember the Senate has only 100 members while the House has 435.

Do the math: senators are trading at more than four times the rate of House members on a per-capita basis. For every trade a typical House member makes, a senator makes four.

This disparity likely reflects both opportunity and culture. Senators serve six-year terms instead of two, giving them more stability and perhaps more confidence to engage in active trading. They're often wealthier, with deeper connections to financial advisors and Wall Street. And they sit on fewer but more powerful committees—committees that oversee entire sectors of the economy.

Politicians from California made 20 trades—more than any other state, and more than Texas (18 trades) and New York (16 trades) despite those states also having large congressional delegations.

California's dominance reflects two realities: wealth and industry. California sends some of the wealthiest members to Congress, representing districts in Silicon Valley, Los Angeles, and San Francisco where tech executives, venture capitalists, and entertainment moguls form the donor base. These politicians often come from wealth themselves or accumulate it quickly through proximity to America's richest industries.

The second factor is sector proximity. California representatives trade heavily in technology stocks like Alphabet (GOOGL), which appeared in 8 trades across the dataset, and Netflix (NFLX), which appeared in 9 trades. When you represent Silicon Valley, trading tech stocks isn't just common—it's expected. But that familiarity breeds risk: these politicians regulate the very companies whose stocks fill their portfolios.

Across all 450 trades, politicians made 250 purchases compared to only 200 sales. They were net buyers of stocks during a period that included Federal Reserve interest rate hikes, bank failures, and ongoing inflation concerns that spooked ordinary investors.

This buying pattern suggests confidence—perhaps too much confidence. While regular Americans worried about their 401(k)s and whether to stay in the market, members of Congress were actively buying individual stocks. Were they simply bullish on America? Or did they have access to information that made them more confident than the rest of us?

When a politician buys $250,000 to $500,000 in pharmaceutical stocks—the median transaction size—and then votes on drug pricing legislation weeks later, the public has every right to question whose interests they're serving.